Keros Therapeutics, Inc. (KROS)

Market Cap	569.43M
Revenue (ttm)	214.71M
Net Income (ttm)	4.21M
Shares Out	40.62M
EPS (ttm)	0.11
PE Ratio	128.67
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	953,713
Open	13.62
Previous Close	13.71
Day's Range	13.62 - 14.38
52-Week Range	9.12 - 72.37
Beta	1.33
Analysts	Buy
Price Target	23.14 (+65.05%)
Earnings Date	May 6, 2025

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 8, 2020
• Employees: 169
• Stock Exchange: NASDAQ
• Ticker Symbol: KROS
• Website: https://www.kerostx.com

Financial Performance

In 2024, Keros Therapeutics's revenue was $3.55 million, an increase of 2250.99% compared to the previous year's $151,000. Losses were -$187.35 million, 22.5% more than in 2023.

Analyst Forecast

According to 12 analysts, the average rating for KROS stock is "Buy." The 12-month stock price forecast is $23.14, which is an increase of 65.05% from the latest price.

Price Target

$23.14

(65.05% upside)

Analyst Consensus: Buy